Prognostic Significance of Systemic Immune Inflammation Index in Urothelial Carcinoma
Author Information
Author(s): Zheng Lei, Wang Zuoping, Li Yunxiang, Ge Si, Zeng Zhiqiang, Gan Lijian, Meng Chunyang, Li Kangsen
Primary Institution: Nanchong Central Hospital, The Second Clinical College, North Sichuan Medical College
Hypothesis
This review assessed the prognostic significance of the systemic immune inflammation index (SII) in patients with urothelial carcinoma.
Conclusion
A low SII may be associated with better recurrence-free survival, cancer-specific survival, and overall survival in patients with urothelial carcinoma.
Supporting Evidence
- A low SII was significantly associated with better recurrence-free survival.
- A low SII was significantly associated with better cancer-specific survival.
- A low SII was significantly associated with better overall survival.
- High SII was an important prognostic biomarker in the UC population.
- Subgroup analysis showed that higher SII was associated with poorer prognosis regardless of treatment regimen.
Takeaway
If you have a low systemic immune inflammation index, it might mean you're more likely to live longer after being treated for bladder cancer.
Methodology
A systematic review and cumulative meta-analysis of 31 studies was conducted following PRISMA criteria.
Potential Biases
Potential selection bias due to the retrospective nature of the included studies.
Limitations
The study included only retrospective studies and varied SII cutoff values, which may affect the reliability of the findings.
Participant Demographics
The studies included a diverse population of patients with urothelial carcinoma, primarily from Asia.
Statistical Information
P-Value
P < 0.05
Confidence Interval
95%CI (1.19, 1.56) for RFS, (1.50, 2.34) for CSS, (1.23, 1.64) for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website